Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Gastroparesis, Diabetes Mellitus
Interventions: Placebo, Relamorelin; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 113
States / cities: Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 95 more

Conditions: Type 2 Diabetes
Interventions: icovamenib 100 mg, Placebo; Drug
Lead sponsor: Biomea Fusion Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 20
States / cities: Birmingham, Alabama • Canoga Park, California • Long Beach, California + 17 more

Conditions: Pain
Interventions: Hydrocodone/Acetaminophen Extended Release, Placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 4
States / cities: Owing Mills, Maryland • Austin, Texas • San Marcos, Texas + 1 more

Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Interventions: Retatrutide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 45 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 204
States / cities: Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 159 more

Conditions: Cornelia de Lange Syndrome
Interventions: N-acetyl cysteine, Placebo; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 13 Years to 35 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: X-Linked Retinitis Pigmentosa
Interventions: rAAV2tYF-GRK1-RPGR; Biological
Lead sponsor: Beacon Therapeutics; Industry
Eligibility: 6 Years to 50 Years · Male only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 4
States / cities: Durham, North Carolina • Cincinnati, Ohio • Portland, Oregon + 1 more

Conditions: Obesity
Interventions: Liraglutide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 9
States / cities: Tucson, Arizona • Denver, Colorado • Meridian, Idaho + 6 more

Conditions: Healthy Volunteers
Interventions: ETI-204, "Anthim", placebo; Drug · Other
Lead sponsor: Elusys Therapeutics; Other
Eligibility: 18 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Early Alzheimer's Disease
Interventions: Semagludtide, Placebo (semaglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 1,840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 96
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 76 more

Conditions: Tourette's Disorder
Interventions: Omega-3 Fatty Acids, Olive oil; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 6 Years to 18 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Second Trimester Abortion
Interventions: Laminaria, Dilapan-S; Device
Lead sponsor: Planned Parenthood of Greater New York; Other
Eligibility: 18 Years and older · Female only
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Schizophrenia, Schizoaffective Disorder, Substance Use Disorders
Interventions: Brexpiprazole, Treatment as Usual; Drug · Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 4
States / cities: Augusta, Georgia • Boston, Massachusetts • Worcester, Massachusetts + 1 more

Conditions: Dyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases, Hyperlipoproteinemia
Interventions: LY3561774, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: Waterbury, Connecticut • Oxon Hill, Maryland • Fall River, Massachusetts + 3 more

Conditions: Cancer
Interventions: lapatinib, placebo matching lapatinib; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 4
States / cities: Detroit, Michigan • Lebanon, New Hampshire • Durham, North Carolina + 1 more

Conditions: Psoriasis
Interventions: Etanercept plus tacrolimus; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Respiratory Distress Syndrome, Newborn
Interventions: Betamethasone; Drug
Lead sponsor: Emory University; Other
Eligibility: Female only
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: HIV Infections
Interventions: Tenofovir disoproxil fumarate; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: San Francisco, California • Baltimore, Maryland • Seattle, Washington

Conditions: Menopause
Interventions: Probiotic, Placebo; Dietary Supplement · Other
Lead sponsor: Lallemand Health Solutions; Industry
Eligibility: 40 Years to 59 Years · Female only
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: Lake Worth, Florida • Port Saint Lucie, Florida • Atlanta, Georgia + 2 more

Conditions: Liver Cirrhosis, Biliary
Interventions: Obeticholic Acid (OCA), Placebo; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 11
States / cities: Rialto, California • Sacramento, California • Miami, Florida + 8 more

Conditions: Essential Thrombocythemia
Interventions: Ropeginterferon alfa-2b, Anagrelide; Biological · Drug
Lead sponsor: PharmaEssentia; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 4
States / cities: Scottsdale, Arizona • St Louis, Missouri • Houston, Texas + 1 more

Conditions: Obesity
Interventions: Group 1 (First trimester ultrasound), Group 2 (Second trimester anatomy ultrasound); Diagnostic Test
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pancreatic Carcinoma
Interventions: Best Practice, Quadratus Lumborum Block, Quality-of-Life Assessment, Questionnaire Administration; Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Macular Degeneration
Interventions: rhuFab V2 (ranibizumab); Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 70
States / cities: Tucson, Arizona • Beverly Hills, California • Irvine, California + 60 more

Conditions: Healthy Volunteers, Propionic Acidemia, Methylmalonic Acidemia, Organic Acidemia
Interventions: BBP-671, Placebo; Drug
Lead sponsor: CoA Therapeutics, Inc., a BridgeBio company; Industry
Eligibility: 15 Years to 55 Years
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Topeka, Indiana • Pittsburgh, Pennsylvania • Austin, Texas

Search by objective public record fields.

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy

A Study Comparing the Analgesic Activity of Extended Release Hydrocodone/Acetaminophen (Vicodin® CR) and Placebo in Subjects With Pain Following Bunionectomy Surgery

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Use of N-Acetylcysteine in the Treatment of Repetitive and Self-Injurious Behaviors in Cornelia de Lange Syndrome

Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations

SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity

Intravenous Dose-Escalation Study With ETI-204 in Adult Volunteers

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

Omega-3 Fatty Acids in Tourette's Disorder

Laminaria Compared to Dilapan-S for Cervical Preparation Before Dilation and Evacuation at 18-24 Weeks of Gestation

Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder

A Study of LY3561774 in Participants With Mixed Dyslipidemia

A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval

Etanercept With Tacrolimus for Psoriasis

Antepartum Betamethasone Treatment for Prevention of Respiratory Distress in Infants Born by Elective Cesarean Section

The Safety and Effectiveness of PMPA Prodrug in HIV-Infected Patients

The Effects of a Novel Probiotic Supplement on Menopausal Symptoms and Bone Health

Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

Early Anatomy Scan for Evaluation of Obese Pregnant Women (EASE-O)

Repeat Quadratus Lumborum Block to Reduce Opioid Need in Patients After Pancreatic Surgery

A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration

A First in Human, Dose Escalation Study to Evaluate the Safety and Tolerability of BBP-671 in Healthy Volunteers and Patients With Propionic Acidemia or Methylmalonic Acidemia